Acute Myocardial Injury of Patients with Coronavirus Disease 2019

Huayan Xu; Keke Hou; Hong Xu; Zhenlin Li; Huizhu Chen; Na Zhang; Rong Xu; Hang Fu; Ran Sun; Lingyi Wen; Linjun Xie; Hui Liu; Kun Zhang; Joseph B Selvanayagam; Chuan Fu; Shihua Zhao; Zhigang Yang; Ming Yang; Yingkun Guo

The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.03.05.20031591 doi: medRxiv preprint as antiviral or antibiotic therapy, respiratory support, continuous renal replacement therapy, and extracorporeal membrane oxygenation [ECMO]) were collected from the patients' medical records. Laboratory test results including those of blood routine tests, C-reactive protein (CRP) and D-dimer tests, and blood gas analysis were recorded and compared. The levels of cardiac injury markers including lactate dehydrogenase (LDH), hydroxybutyrate dehydrogenase, creatine kinase (CK), CK-MB, myoglobin (MYO), amino N-terminal pro-brain natriuretic peptide, and TNT-HSST were determined at admission. The AMI group was defined as patients with TNT-HSST serum levels > 99th percentile upper reference limit (>28 pg/ml). 6 The group with cardiac marker abnormalities but non-definite AMI was defined as patients with TNT-HSST serum levels < 28pg/ml but increase in the levels of any of the other abovementioned cardiac markers. The group without cardiac marker abnormalities comprised patients without elevation in the levels of any of the cardiac markers. Chest computed tomography (CT) was performed on the day of admission. The period of illness onset to admission was defined from the day when signs or symptoms were first noticed to the day of admission. All enrolled patients underwent two-dimensional echocardiography (2D echo) and electrocardiography (ECG) during hospitalization.